

NRG GY005

Advancing Research. Improving Lives.™



Canadian Cancer Trials Group  Groupe canadien des essais sur le cancer

**NRG GY005: Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with platinum-resistant recurrent Ovarian Cancer**

**Trial setting: tumour type/stage:** recurrent platinum-resistant or – refractory ovarian cancer  
**Sponsor(s):** CTEP/NCI U.S.  
**Planned No. of patients:** 208 (Phase II)+ 354 (Phase III): Total of 562  
**Current accrual status:** To reopen in 4Q 2018

PRR OvCa patients  
 ECOG 0-2  
 Measurable disease  
 ≤ 2 prior regimens in the recurrent setting  
 No prior bevacizumab in the recurrent setting  
 gBRCAm status is not required at study entry

1:1:1



Cediranib 30mg/d +  
 Olaparib 200mg bid

Cediranib 30 mg  
 daily

PLD  
 wkly Paclitaxel  
 Topotecan

PFS, OS